{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:34:56Z","timestamp":1788305696925,"version":"build-2803163510"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ajo.2025.07.025","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T17:35:41Z","timestamp":1753724141000},"page":"555-570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Ocular Delivery of Viral Vectors for Retinal and Choroidal Vascular Diseases: A Review"],"prefix":"10.1016","volume":"279","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5116-4257","authenticated-orcid":false,"given":"Rajat","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3869-4258","authenticated-orcid":false,"given":"Sydney V.","family":"Oraskovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9625-0121","authenticated-orcid":false,"given":"David V.","family":"Schaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2025.07.025_bib0001","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.preteyeres.2015.06.002","article-title":"Molecular pathogenesis of retinal and choroidal vascular diseases","volume":"49","author":"Campochiaro","year":"2015","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"10.1016\/j.ajo.2025.07.025_bib0002","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.survophthal.2024.05.002","article-title":"Gene and cell therapy for age-related macular degeneration: a review","volume":"69","author":"Trinc\u00e3o-Marques","year":"2024","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2025.07.025_bib0003","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.survophthal.2022.01.009","article-title":"Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: a systematic review and meta-analysis","volume":"67","author":"Im","year":"2022","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.07.025_bib0004","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/eye.2015.217","article-title":"Ranibizumab for the treatment of wet AMD: a summary of real-world studies","volume":"30","author":"Chong","year":"2016","journal-title":"Eye"},{"issue":"10436","key":"10.1016\/j.ajo.2025.07.025_bib0005","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ajo.2025.07.025_bib0006","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"10.1016\/j.ajo.2025.07.025_bib0007","doi-asserted-by":"crossref","first-page":"491","DOI":"10.59249\/HWID7537","article-title":"Ocular gene therapy: an overview of viral vectors, immune responses, and future directions","volume":"97","author":"Banou","year":"2024","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.ajo.2025.07.025_bib0008","doi-asserted-by":"crossref","first-page":"821","DOI":"10.18609\/CGTI.2024.095","article-title":"Advancing AAV production with high-throughput screening and transcriptomics","volume":"10","author":"Reid","year":"2024","journal-title":"Cell Gene Ther Insights"},{"issue":"2","key":"10.1016\/j.ajo.2025.07.025_bib0009","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/1566523214666140302193709","article-title":"Basic biology of adeno-associated virus (AAV) vectors used in gene therapy","volume":"14","author":"Balakrishnan","year":"2014","journal-title":"Curr Gene Ther"},{"issue":"1","key":"10.1016\/j.ajo.2025.07.025_bib0010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mt.2009.255","article-title":"Effect of genome size on AAV vector packaging","volume":"18","author":"Wu","year":"2010","journal-title":"Mol Ther"},{"issue":"R1","key":"10.1016\/j.ajo.2025.07.025_bib0011","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1093\/hmg\/ddz148","article-title":"Next-generation AAV vectors-do not judge a virus (only) by its cover","volume":"28","author":"Domenger","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ajo.2025.07.025_bib0012","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.omtn.2016.12.006","article-title":"Inclusion of the Woodchuck hepatitis virus posttranscriptional regulatory element enhances AAV2-driven transduction of mouse and human retina","volume":"6","author":"Patr\u00edcio","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"issue":"16","key":"10.1016\/j.ajo.2025.07.025_bib0013","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1128\/JVI.00649-08","article-title":"Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle","volume":"82","author":"Penaud-Budloo","year":"2008","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.ajo.2025.07.025_bib0014","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","article-title":"Durability of transgene expression after rAAV gene therapy","volume":"30","author":"Muhuri","year":"2022","journal-title":"Mol Ther"},{"issue":"22","key":"10.1016\/j.ajo.2025.07.025_bib0015","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1056\/NEJMoa2414783","article-title":"Sustained clinical benefit of AAV gene therapy in severe hemophilia B","volume":"392","author":"Reiss","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajo.2025.07.025_bib0016","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/v16030442","article-title":"Natural adeno-associated virus serotypes and engineered adeno-associated virus capsid variants: tropism differences and mechanistic insights","volume":"16","author":"Lopez-Gordo","year":"2024","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.ajo.2025.07.025_bib0017","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3390\/cells12050785","article-title":"Various AAV serotypes and their applications in gene therapy: an overview","volume":"12","author":"Issa","year":"2023","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.ajo.2025.07.025_bib0018","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","article-title":"AAV vectors: the Rubik's cube of human gene therapy","volume":"30","author":"Pupo","year":"2022","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.ajo.2025.07.025_bib0019","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1128\/JVI.79.1.214-224.2005","article-title":"Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice","volume":"79","author":"Nakai","year":"2005","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.ajo.2025.07.025_bib0020","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/mt.2011.72","article-title":"Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates","volume":"19","author":"Gray","year":"2011","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.ajo.2025.07.025_bib0021","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ajo.2025.07.025_bib0022","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.coph.2015.08.002","article-title":"Engineering the AAV capsid to optimize vector-host-interactions","volume":"24","author":"B\u00fcning","year":"2015","journal-title":"Curr Opin Pharmacol"},{"issue":"7","key":"10.1016\/j.ajo.2025.07.025_bib0023","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrg3742","article-title":"Engineering adeno-associated viruses for clinical gene therapy","volume":"15","author":"Kotterman","year":"2014","journal-title":"Nat Rev Genet"},{"issue":"189","key":"10.1016\/j.ajo.2025.07.025_bib0037","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005708","article-title":"In vivo\u2013directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ajo.2025.07.025_bib0024","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/TACG.S383453","article-title":"Adeno-associated virus (AAV) -based gene therapies for retinal diseases: where are we?","volume":"16","author":"Ail","year":"2023","journal-title":"Appl Clin Genet"},{"key":"10.1016\/j.ajo.2025.07.025_bib0025","article-title":"Gene therapy advances: a meta-analysis of AAV usage in clinical settings","volume":"8","author":"Au","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ajo.2025.07.025_bib0026","first-page":"0291","article-title":"AAV for gene therapy in ocular diseases: progress and prospects","volume":"6","author":"He","year":"2023","journal-title":"Research (Wash D C)"},{"key":"10.1016\/j.ajo.2025.07.025_bib0027","doi-asserted-by":"crossref","first-page":"1148795","DOI":"10.3389\/fddev.2023.1148795","article-title":"Yl\u00e4-Herttuala S. AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery. Original research","volume":"3","author":"Koponen","year":"2023","journal-title":"Front Drug Deliv"},{"issue":"10","key":"10.1016\/j.ajo.2025.07.025_bib0028","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ophtha.2021.03.031","article-title":"Durability of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease: phase 3 results at 3 and 4 years","volume":"128","author":"Maguire","year":"2021","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2025.07.025_bib0029","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000526317","article-title":"Gene therapy for inherited retinal disease: long-term durability of effect","volume":"66","author":"Leroy","year":"2023","journal-title":"Ophthalmic Res"},{"issue":"5","key":"10.1016\/j.ajo.2025.07.025_bib0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41434-020-0168-2","article-title":"Retinal gene therapy: an eye-opener of the 21st century","volume":"28","author":"Askou","year":"2021","journal-title":"Gene Therapy"},{"issue":"12","key":"10.1016\/j.ajo.2025.07.025_bib0031","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/mt.2009.181","article-title":"Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous","volume":"17","author":"Dalkara","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajo.2025.07.025_bib0032","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-0716-3409-7_17","article-title":"Intravitreal injection of AAV for the transduction of mouse retinal ganglion cells","volume":"2708","author":"Nieuwenhuis","year":"2023","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.ajo.2025.07.025_bib0033","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fnins.2017.00174","article-title":"Retinal gene therapy: surgical vector delivery in the translation to clinical trials","volume":"11","author":"Ochakovski","year":"2017","journal-title":"Front Neurosci"},{"key":"10.1016\/j.ajo.2025.07.025_bib0034","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.omtm.2020.01.002","article-title":"Suprachoroidal and subretinal injections of AAV using transscleral microneedles for retinal gene delivery in nonhuman primates","volume":"16","author":"Yiu","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6","key":"10.1016\/j.ajo.2025.07.025_bib0035","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/jop.2019.0126","article-title":"Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases","volume":"36","author":"Kansara","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"issue":"13-14","key":"10.1016\/j.ajo.2025.07.025_bib0036","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/hum.2020.281","article-title":"Host immune responses after suprachoroidal delivery of aav8 in nonhuman primate eyes","volume":"32","author":"Chung","year":"2021","journal-title":"Hum Gene Ther"},{"issue":"14","key":"10.1016\/j.ajo.2025.07.025_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/iovs.65.14.1","article-title":"Design and characterization of a novel intravitreal dual-transgene genetic medicine for neovascular retinopathies","volume":"65","author":"Calton","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.ajo.2025.07.025_bib0039","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1038\/s41467-024-48221-4","article-title":"An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species","volume":"15","author":"Luo","year":"2024","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.ajo.2025.07.025_bib0040","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.ymthe.2020.06.029","article-title":"Gene therapy intervention in neovascular eye disease: a recent update","volume":"28","author":"Lin","year":"2020","journal-title":"Mol Ther"},{"issue":"13-14","key":"10.1016\/j.ajo.2025.07.025_bib0041","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1089\/hum.2021.132","article-title":"Low-dose recombinant adeno-associated virus-mediated inhibition of vascular endothelial growth factor can treat neovascular pathologies without inducing retinal vasculitis","volume":"32","author":"Cheng","year":"2021","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.ajo.2025.07.025_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1350-9462(02)00043-5","article-title":"Vascular endothelial growth factors and angiogenesis in eye disease","volume":"22","author":"Witmer","year":"2003","journal-title":"Prog Retin Eye Res"},{"issue":"16","key":"10.1016\/j.ajo.2025.07.025_bib0043","doi-asserted-by":"crossref","first-page":"9424","DOI":"10.3390\/ijms23169424","article-title":"Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review","volume":"23","author":"Liberski","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.ajo.2025.07.025_bib0044","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/jcmm.13086","article-title":"A novel bispecific molecule delivered by recombinant AAV suppresses ocular inflammation and choroidal neovascularization","volume":"21","author":"Li","year":"2017","journal-title":"J Cell Mol Med"},{"issue":"3","key":"10.1016\/j.ajo.2025.07.025_bib0045","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3390\/ph18030293","article-title":"Preclinical retinal disease models: applications in drug development and translational research","volume":"18","author":"Soundara Pandi","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.ajo.2025.07.025_bib0046","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.preteyeres.2010.05.003","article-title":"Animal models of choroidal and retinal neovascularization","volume":"29","author":"Grossniklaus","year":"2010","journal-title":"Prog Retin Eye Res"},{"issue":"10","key":"10.1016\/j.ajo.2025.07.025_bib0047","first-page":"3158","article-title":"VEGF is major stimulator in model of choroidal neovascularization","volume":"41","author":"Kwak","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.07.025_bib0048","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3389\/fphar.2020.00873","article-title":"Exploration of oxygen-induced retinopathy model to discover new therapeutic drug targets in retinopathies","volume":"11","author":"V\u00e4h\u00e4tupa","year":"2020","journal-title":"Front Pharmacol"},{"issue":"14","key":"10.1016\/j.ajo.2025.07.025_bib0049","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1167\/iovs.62.14.26","article-title":"Retinal and choroidal vascular diseases: past, present, and future: the 2021 proctor lecture","volume":"62","author":"Campochiaro","year":"2021","journal-title":"Invest Opthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.ajo.2025.07.025_bib0050","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3390\/genes15060720","article-title":"Gene therapy for non-hereditary retinal disease: age-related macular degeneration, diabetic retinopathy, and beyond","volume":"15","author":"Rowe","year":"2024","journal-title":"Genes"},{"issue":"2","key":"10.1016\/j.ajo.2025.07.025_bib0051","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/hum.2006.17.167","article-title":"Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial","volume":"17","author":"Campochiaro","year":"2006","journal-title":"Hum Gene Ther"},{"issue":"10089","key":"10.1016\/j.ajo.2025.07.025_bib0052","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","article-title":"Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial","volume":"390","author":"Heier","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ajo.2025.07.025_bib0053","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymthe.2018.11.003","article-title":"Preclinical evaluation of ADVM-022, a novel gene therapy approach to treating wet age-related macular degeneration","volume":"27","author":"Grishanin","year":"2019","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.ajo.2025.07.025_bib0054","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41433-021-01842-1","article-title":"Review of gene therapies for age-related macular degeneration","volume":"36","author":"Khanani","year":"2022","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ajo.2025.07.025_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102394","article-title":"Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study","volume":"67","author":"Khanani","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"14","key":"10.1016\/j.ajo.2025.07.025_bib0056","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/iovs.65.14.1","article-title":"Design and characterization of a novel intravitreal dual-transgene genetic medicine for neovascular retinopathies","volume":"65","author":"Calton","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.07.025_bib0057","unstructured":"Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema. Accessed July 22, 2021. https:\/\/investors.adverum.com\/press_releases\/news-details\/2021\/Adverum-Provides-Update-on-ADVM-022-and-the-INFINITY-Trial-in-Patients-with-Diabetic-Macular-Edema\/default.aspx"},{"key":"10.1016\/j.ajo.2025.07.025_bib0058","unstructured":"Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path. Accessed January 10, 2025. https:\/\/ir.4dmoleculartherapeutics.com\/news-releases\/news-release-details\/4dmt-announces-positive-interim-data-4d-150-spectra-clinical"},{"key":"10.1016\/j.ajo.2025.07.025_bib0059","unstructured":"REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE\u00ae Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery. Accessed November 3, 2023. https:\/\/regenxbio.gcs-web.com\/news-releases\/news-release-details\/regenxbio-presents-positive-one-year-data-phase-ii-altituder"},{"issue":"6","key":"10.1016\/j.ajo.2025.07.025_bib0061","doi-asserted-by":"crossref","first-page":"E517","DOI":"10.1073\/pnas.1218933110","article-title":"Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement","volume":"110","author":"Cideciyan","year":"2013","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1016\/j.ajo.2025.07.025_bib0062","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.oret.2021.03.016","article-title":"Perifoveal chorioretinal atrophy after subretinal voretigene neparvovec-rzyl for RPE65-mediated Leber congenital amaurosis","volume":"6","author":"Gange","year":"2022","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"10.1016\/j.ajo.2025.07.025_bib0063","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.oret.2023.08.017","article-title":"Classification and growth rate of chorioretinal atrophy after voretigene neparvovec-rzyl for RPE65-mediated retinal degeneration","volume":"8","author":"Bommakanti","year":"2024","journal-title":"Ophthalmol Retina"},{"issue":"15-16","key":"10.1016\/j.ajo.2025.07.025_bib0064","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1089\/hum.2024.017","article-title":"An open-label phase II study assessing the safety of bilateral, sequential administration of retinal gene therapy in participants with choroideremia: The GEMINI Study","volume":"35","author":"MacLaren","year":"2024","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ajo.2025.07.025_bib0065","unstructured":"REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024. Accessed October 21, 2024. https:\/\/ir.regenxbio.com\/news-releases\/news-release-details\/regenxbio-presents-positive-data-phase-ii-study-subretinal-abbv"},{"issue":"2","key":"10.1016\/j.ajo.2025.07.025_bib0066","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/gt.2014.115","article-title":"Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates","volume":"22","author":"Kotterman","year":"2015","journal-title":"Gene Ther"},{"issue":"19-20","key":"10.1016\/j.ajo.2025.07.025_bib0067","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1089\/hum.2022.216","article-title":"Neonatal Fc receptor inhibition enables adeno-associated virus gene therapy despite pre-existing humoral immunity","volume":"34","author":"Horiuchi","year":"2023","journal-title":"Hum Gene Ther"},{"issue":"9","key":"10.1016\/j.ajo.2025.07.025_bib0068","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.3390\/jcm14093205","article-title":"Gene therapy in diabetic retinopathy and diabetic macular edema: an update","volume":"14","author":"Odio-Herrera","year":"2025","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.ajo.2025.07.025_bib0069","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.3390\/biomedicines11123221","article-title":"Recent developments in gene therapy for neovascular age-related macular degeneration: a review","volume":"11","author":"Finocchio","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ajo.2025.07.025_bib91","unstructured":"Retinal Physician. Fellow eye dosing of gene therapy found safe, effective. Accessed August 14, 2025. https:\/\/www.retinalphysician.com\/issues\/2024\/october\/subretinal-delivery-of-abbv-rgx-314\/, 2024."},{"issue":"13","key":"10.1016\/j.ajo.2025.07.025_bib0070","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1167\/iovs.17-22431","article-title":"Systemic biodistribution and intravitreal pharmacokinetic properties of bevacizumab, ranibizumab, and aflibercept in a nonhuman primate model","volume":"58","author":"Christoforidis","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.07.025_bib0071","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.ajo.2025.07.025_bib0072","article-title":"Advances and challenges in gene therapy for inherited retinal dystrophies: a comprehensive review","volume":"16","author":"Jain","year":"2024","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.ajo.2025.07.025_bib0073","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.ymthe.2025.01.028","article-title":"Characterization of the ocular inflammatory response to AAV reveals divergence by sex and age","volume":"33","author":"Clare","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajo.2025.07.025_bib0074","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.2147\/DDDT.S383101","article-title":"Progress and challenges of anti-VEGF agents and their sustained-release strategies for retinal angiogenesis","volume":"16","author":"Xu","year":"2022","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"10.1016\/j.ajo.2025.07.025_bib0075","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ophtha.2017.08.038","article-title":"The progression of geographic atrophy secondary to age-related macular degeneration","volume":"125","author":"Fleckenstein","year":"2018","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2025.07.025_bib0076","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ng.3448","article-title":"A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants","volume":"48","author":"Fritsche","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.ajo.2025.07.025_bib0077","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"10.1016\/j.ajo.2025.07.025_bib0078","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajo.2025.07.025_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100906","article-title":"Incomplete response to Anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities","volume":"82","author":"Mettu","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajo.2025.07.025_bib0080","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.exer.2015.04.004","article-title":"Retinal fibrosis in diabetic retinopathy","volume":"142","author":"Roy","year":"2016","journal-title":"Exp Eye Res"},{"issue":"5","key":"10.1016\/j.ajo.2025.07.025_bib0081","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMra1706910","article-title":"Gene therapy","volume":"381","author":"High","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ajo.2025.07.025_bib0082","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1167\/iovs.64.15.47","article-title":"The diabetic retinopathy \"pandemic\" and evolving global strategies: the 2023 Friedenwald Lecture","volume":"64","author":"Wong","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.07.025_bib0083","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/OPTH.S269162","article-title":"Ten-year real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration","volume":"15","author":"Cheema","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ajo.2025.07.025_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2022.101160","article-title":"Endpoints for clinical trials in ophthalmology","volume":"97","author":"Schmetterer","year":"2023","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajo.2025.07.025_bib0085","unstructured":"ICER. Voretigene neparvovec for inherited retinal disease: final evidence report. Accessed May 24, 2025. https:\/\/icer.org, 2019."},{"issue":"1","key":"10.1016\/j.ajo.2025.07.025_bib0087","article-title":"Annuity payments can increase patient access to innovative cell and gene therapies under England's net budget impact test","volume":"5","author":"J\u00f8rgensen","year":"2017","journal-title":"J Mark Access Health Policy"},{"issue":"2","key":"10.1016\/j.ajo.2025.07.025_bib0088","article-title":"Spark's gene therapy price tag: $850,000","volume":"36","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.ajo.2025.07.025_bib0089","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40259-023-00629-y","article-title":"AAV-based strategies for treatment of retinal and choroidal vascular diseases: advances in age-related macular degeneration and diabetic retinopathy therapies","volume":"38","author":"Castro","year":"2024","journal-title":"BioDrugs"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425003885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425003885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:40:17Z","timestamp":1760186417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939425003885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":88,"alternative-id":["S0002939425003885"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.07.025","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular Delivery of Viral Vectors for Retinal and Choroidal Vascular Diseases: A Review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}